<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04835805</url>
  </required_header>
  <id_info>
    <org_study_id>GO42273</org_study_id>
    <secondary_id>2020-003674-41</secondary_id>
    <nct_id>NCT04835805</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-mutant Advanced Melanoma.</brief_title>
  <official_title>A Phase Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, pharmacokinetics, and activity of belvarafenib as a&#xD;
      single agent and in combination with either cobimetinib or cobimetinib plus atezolizumab in&#xD;
      patients with NRAS-mutant advanced melanoma who have received anti-PD-1/PD-L1 therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate three treatment regimens in three arms: a belvarafenib monotherapy&#xD;
      arm (Belva arm) of up to 15 patients; a belvarafenib plus cobimetinib arm (Belva + Cobi arm)&#xD;
      in an initial dose-finding phase followed by an expansion phase and a belvarafenib plus&#xD;
      cobimetinib plus atezolizumab arm (Belva + Cobi + Atezo arm) in a run-in phase followed by an&#xD;
      expansion phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2021</start_date>
  <completion_date type="Anticipated">November 11, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Dose Limiting Toxicity (DLTs)</measure>
    <time_frame>28 Days from Cycle 1, Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>From Cycle 1, Day 1 Up to 4 Years</time_frame>
    <description>Severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) according to RECIST v1.1</measure>
    <time_frame>Up to Approximately 4 Years</time_frame>
    <description>Defined as the percentage of participants with a CR or PR on two consecutive occasions &gt;/= 4 weeks apart, as determined by the investigator according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) according to RECIST v1.1</measure>
    <time_frame>Up to Approximately 4 Years</time_frame>
    <description>Defined as the time from the first study treatment to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) according to RECIST v1.1</measure>
    <time_frame>Up to Approximately 4 Years</time_frame>
    <description>Defined as the time from the first occurrence of a confirmed objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to Approximately 4 Years</time_frame>
    <description>Defined as the time from the first study treatment to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of belvarafenib at specified timepoints</measure>
    <time_frame>Up to 30 Days After the Final Dose of Study Drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of cobimetinib at specified timepoints</measure>
    <time_frame>Up to 30 Days After the Final Dose of Study Drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of atezolizumab at specified timepoints</measure>
    <time_frame>Up to 30 Days After the Final Dose of Study Drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of atezolizumab anti-drug antibody (ADA)</measure>
    <time_frame>Up to 30 Days After the Final Dose of Study Drug</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Belvarafenib Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily (BID), continuous dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belvarafenib Plus cobimetinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recommended dose (RD) and schedule of belvarafenib and cobimetinib selected based on the safety data, tolerability, pharmacokinetics, and anti-tumor activity tested in dose-finding phase followed by an expansion phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belvarafenib Plus Cobimetinib Plus Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recommended dose (RD) and schedule of belvarafenib and cobimetinib plus atezolizumab IV infusion every 4 weeks (Q4W) followed by an expansion phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belvarafenib</intervention_name>
    <description>Twice daily (BID), continuous dosing</description>
    <arm_group_label>Belvarafenib Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib</intervention_name>
    <description>Once daily (QD) 21 days, 7 days off</description>
    <arm_group_label>Belvarafenib Plus cobimetinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Once every 4 weeks (Q4W)</description>
    <arm_group_label>Belvarafenib Plus Cobimetinib Plus Atezolizumab</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1&#xD;
&#xD;
          -  Histologically confirmed, metastatic (recurrent or de novo Stage IV) or unresectable&#xD;
             locally advanced (Stage III) cutaneous melanoma, that has progressed on or after&#xD;
             treatment with anti-PD-1 or anti-PD-L1 therapy. Patients may have received up to two&#xD;
             lines of systemic cancer therapy. Treatment with anti-PD-1/PD-L1 in the adjuvant&#xD;
             setting is acceptable. Patients must have progressive disease at study entry&#xD;
&#xD;
          -  Documentation of NRAS mutation-positive within 5 years prior to screening&#xD;
&#xD;
          -  Tumor specimen availability&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  Measurable disease per RECIST v1.1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with systemic immunotherapy agents (e.g., anti-CTLA4, anti-PD(L)1, cytokine&#xD;
             therapy, investigational therapy, etc.) within 28 days prior to C1D1&#xD;
&#xD;
          -  Symptomatic, untreated, or actively progressing CNS metastases&#xD;
&#xD;
          -  History or signs/symptoms of clinically significant cardiovascular disease&#xD;
&#xD;
          -  Known clinically significant liver disease&#xD;
&#xD;
          -  History of autoimmune disease or immune deficiency&#xD;
&#xD;
          -  Prior treatment with a MEK inhibitor (cobimetinib arm)&#xD;
&#xD;
          -  History of or evidence of retinal pathology on ophthalmologic examination (cobimetinib&#xD;
             arm)&#xD;
&#xD;
          -  History of immune-related AE attributed to prior anti-PD(L)1 therapy that resulted in&#xD;
             permanent discontinuation of anti-PD(L)1 therapy (atezolizumab arm)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference study ID GO42273 whttps://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center UCI</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family CCC</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC - SCRI - PPDS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203-1625</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre-East Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8M2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital; Department of Med Oncology</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Sir Mortimer B. Davis General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim GmbH Universitätsklinikum</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center - PPDS</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center - PPDS</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oslo universitetssykehus HF</name>
      <address>
        <city>Oslo</city>
        <zip>0379</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Norway</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

